Adage Capital Partners LP Form 8.3 - Horizon Therapeutics PLC (9156N)

TIDMTTM TIDMHZNP

RNS Number : 9156N

Adage Capital Partners LP

27 September 2023

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY INFORMATION 
 
Name of person dealing (Note  Adage Capital Partners GP, L.L.C. 
 1) 
Company dealt in              Horizon Therapeutics PLC 
                              ================================= 
Class of relevant security    US$0.0001 ordinary shares 
 to which the dealings being 
 disclosed relate (Note 2) 
                              ================================= 
Date of dealing               27(th) of September 2023 
                              ================================= 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 
                                         Long               Short 
                             Number      (%)     Number       (%) 
                             =========  ======  ===========  ====== 
(1) Relevant securities      2,986,633 1.30% 
                             =================  =================== 
(2) Derivatives (other 
 than options) 
                             =================  =================== 
(3) Options and agreements 
 to purchase/sell 
                             =================  =================== 
Total 
                             =================  =================== 
 
 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 
Class of relevant security:                Long                Short 
                              Number        (%)     Number         (%) 
                              =========    ======  ===========    ====== 
(1) Relevant securities 
                              ===================  ===================== 
 
  (2) Derivatives (other 
  than options) 
                              ===================  ===================== 
 
  (3) Options and agreements 
  to purchase/sell 
                              ===================  ===================== 
Total 
                              ===================  ===================== 
 
 

Ap20

   1.       DEALINGS (Note 4) 
   (a)      Purchases and sales 
 
 
  Purchase/sale            Number of relevant        Price per unit 
                           securities                (Note 5) 
      Sale                    141                     115.75 
                  ===========================  ==================== 
 
 
 
 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product      Nature of transaction  Number of relevant   Price per 
 name,        (Note 6)               securities           unit 
 e.g. CFD                            (Note 7)             (Note 5) 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing, selling, purchasing or varying 
 
Product     Writing,      Number of       Exercise  Type,            Expiry  Option 
 name,       selling,      securities      price     e.g. American,   date    money paid/received 
 e.g. call   purchasing,   to which                  European                 per unit 
 option      varying       the option                etc.                     (Note 5) 
             etc.          relates (Note 
                           7) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     5) 
 
 
   (d)      Other dealings (including transactions in respect of new securities) (Note 4) 
 
Nature of transaction         Details      Price per unit 
 (Note 8)                                   (if applicable) 
                                            (Note 5) 
 
 

Ap21

   2.       OTHER INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

 
   Full details of any agreement, arrangement or understanding between 
    the person disclosing and any other person relating to the voting 
    rights of any relevant securities under any option referred to 
    on this form or relating to the voting rights or future acquisition 
    or disposal of any relevant securities to which any derivative 
    referred to on this form is referenced. If none, this should be 
    stated. 
 
 
   Is a Supplemental Form 8 attached? (Note 9)                                              NO 
 
Date of disclosure            27(th) of September 2023 
Contact name                  Chris Palmer 
                              ======================== 
Telephone number              617-867-2514 
                              ======================== 
If a connected EFM, name 
 of offeree/offeror with 
 which connected 
                              ======================== 
If a connected EFM, state 
 nature of connection (Note 
 10) 
                              ======================== 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPFDLLLXKLZBBQ

(END) Dow Jones Newswires

September 28, 2023 02:00 ET (06:00 GMT)